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Abstract. The Ƣ-herpesviruses Epstein-Barr virus and 
Kaposi's sarcoma-associated herpesvirus are successful 
pathogens, each infecting a large proportion of the human 
population. These viruses persist for the life of the host and 
may each contribute to a number of malignancies, for which 
there are currently no cures. Large-scale proteomic-based 
approaches provide an excellent means of increasing the 
collective understanding of the proteomes of these complex 
viruses and elucidating their numerous interactions within the 
infected host cell. These large-scale studies are important for WKHLGHQWLÀFDWLRQRIWKHLQWULFDFLHVRIYLUDOLQIHFWLRQDQGWKH
development of novel therapeutics against these two important 
pathogens.
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1. Introduction
The Epstein-Barr virus (EBV), also referred to as human 
herpesvirus 4 (HHV-4), was WKHÀUVWKXPDQRQFRJHQLFYLUXV
to be isolated 50 years ago by Epstein and co-workers from 
lymphoblasts cultured from a Burkitt's lymphoma (1). Thirty 
\HDUVODWHUKHUSHVYLUDO'1$ZDVLGHQWLÀHGLQFHOOVRI.DSRVL
V
sarcoma (KS), giving rise to a new virus, KS-associated 
herpesvirus (KSHV), also referred to as HHV-8 (2). KSHV 
was shown to be highly related to EBV and, therefore, repre-
sented the second human Ƣ-herpesvirus. To date, these are 
the only known oncogenic human herpesviruses and are each 
associated with numerous malignancies (Table I).
Over 90% of the global adult population is seropositive for 
EBV and infection usually occurs asymptomatically in early 
childhood (3,4). However, primary infection during adoles-
cence often results in infectious mononucleosis, which is 
characterised by T-cell hyperproliferation with a strong CD8+ 
response, with affected individuals suffering from flu-like 
symptoms and severe fatigue. Furthermore, only a minute 
proportion of those infected with EBV develop malignant 
diseases (5) and these diseases are invariably associated with 
immune suppression, either iatrogenic, or due to human immu-QRGHÀFLHQF\YLUXV+,9 or malaria co-infection (6).
The KSHV prevalence in northern Europe is VLJQLÀFDQWO\ 
lower compared to that of EBV, with approximately 3% of the 
population testing seropositive (7,8). However, several parts of 
Africa have an incidence rate of >80%, whereas intermediate 
rates are found in the Mediterranean (9,10). Concurrent with 
these findings, KS is one of the most common cancers in 
sub-Saharan Africa, where individuals are often co-infected 
with KSHV and HIV (11).
The two Ƣ-herpesviruses readily infect B lymphocytes, 
where they establish a lifelong reservoir (12,13). However, 
initial infection and replication may also occur in oral 
epithelial cells, allowing transmission of the viruses via 
contaminated saliva (12-17). Similar to all members of the 
herpesvirus family, EBV and KSHV have a biphasic life cycle, 
consisting of a latent phase and a lytic replication cycle (18). 
Following primary infection, viral latency is established with 
the viral genome maintained as a circularised episome in the 
nucleus of the host cell. During this phase of infection, no 
infectious virions are produced. A limited number of genes are 
expressed during latency, encoding proteins that promote cell 
survival and proliferation, in order to avoid loss of the viral 
episome. While this proliferation is limited by the immune 
system in healthy individuals, individuals with a compromised 
immune system, under conditions such as iatrogenic immu-QRVXSSUHVVLRQVXIIHULQJIURPFRQJHQLWDOLPPXQRGHÀFLHQF\
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or co-infected with HIV, may develop lymphoproliferative 
disorders (19).
EBV latency is associated with at least four gene expression 
programmes, termed latency 0, I, II and III. Latency III, which 
is found in the B cells of post-transplant lymphoproliferative 
disease (PTLD) patients and in in vitro immortalised B cells, GLVSOD\VWKHEURDGHVWJHQHH[SUHVVLRQSURÀOH, with expression 
of all the EBV-encoded nuclear antigens (EBNA1, 2, 3A, 
3B, 3C and leader protein), three latent membrane proteins 
(LMP1, 2A and 2B) and several non-coding RNAs, such as 
the Epstein-Barr virus-encoded small RNAs (EBERs) and 
microRNAs (miRNAs) (5,20,21). Latency II, which is observed 
in Hodgkin's lymphoma and EBV-associated carcinomas, is 
more restrictive, as only EBNA1 and the LMPs are expressed 
(along with EBERs). Latency I, the most restrictive latency 
programme associated with malignancy is found in Burkitt's 
lymphoma, where, along with the EBERs, EBNA1 is the only 
EBV protein expressed. However, in resting memory B cells, 
the latent reservoir in immunocompetent individuals, no viral 
proteins are expressed, which is known as latency 0 (22,23).
It is considered that primary infection by EBV initially 
requires the latency III transcriptional programme in order to 
drive the proliferation and differentiation of B cells to promote 
host colonisation. However, as several of the EBNAs are 
immunodominant, a healthy immune system prevents this from 
evolving into a lymphoproliferative disorder. Therefore, EBV 
possesses various sophisticated mechanisms that promote the 
downregulation of gene expression as latency is established. 
These mechanisms are poorly understood, but it is hypoth-
esized that EBV transcription is sequentially restricted as it 
transits the germinal centre reaction on its way to acquiring a 
memory B-cell phenotype. It is not surprising, therefore, given 
the effect of latency-associated genes on cellular function, that 
all EBV diseases are associated with latency.
KSHV differs from EBV, as lytic replication is essential 
for the most common malignancy associated with this virus, 
i.e., KS. The lytic cycle may be activated by cellular stimuli, VXFKDVK\SR[LDVHFUHWLRQRILQÁDPPDWRU\IDFWRUVRU
co-infection with other viruses, such as human cytomegalo-
virus or HIV (26,27). Lytic replication results in the shedding 
of infectious virions from the B-cell reservoir and subsequent 
infection of endothelial cells, where KS tumours occur (28). 
Although the origin of these cells (blood or lymphatic endo-
thelium) remains to date undetermined (29), it is a hallmark of 
KS tumours that these cells adopt a spindle cell morphology. 
The majority of tumour cells remain latently infected, but low 
levels of virus sporadically enter the lytic cycle, meaning that 
there is always a small percentage of cells undergoing lytic 
infection (30,31). It is hypothesized that lytic replication is HVVHQWLDOIRUWXPRXULJHQHVLVDV.6+9ODWHQF\LVQRWVXIÀFLHQW
to maintain the pool of infected endothelial cells. Furthermore, 
replicating KSHV expresses several oncogenic, angiogenic and 
antiapoptotic gene products that contribute to cancer forma-
tion (32-37), including the secretion of tumour-promoting 
factors, such as interleukin (IL)-6 and IL-8 (38-40).
Other malignancies associated with KSHV include the 
rare B-cell lymphomas primary effusion lymphoma (PEL) 
and multicentric Castleman's disease. Importantly, PEL cells, 
unlike KS-derived cells, are able to maintain high copy 
numbers of the latent KSHV genome when cultured and, 
therefore, provide an essential research tool for studying 
KSHV in vitro (41).
TKHJHQHH[SUHVVLRQSURÀOHRI.6+9LQKHDOWK\LPPX-
nocompetent individuals is currently unknown, as all our 
knowledge is gleaned from studying cancer cell lines or 
histological examination of malignant tissues. However, 
it is known that KSHV also expresses a restricted gene H[SUHVVLRQSURÀOHGXULQJODWHQF\which is essential for the 
viability of these cancer cells. The expressed genes include 
the latency-associated nuclear antigen (LANA)1 (42), the 
cyclin homologue v-cyclin, the viral homologue of the cellular 
FLICE-inhibitory protein vFLIP and kaposin (43,44). Of note, H[SUHVVLRQRIY)/,3DORQHLVVXIÀFLHQWWRDOWHUWKHPRUSKRORJ\
of cultured endothelial cells to the characteristic spindle cells 
of KS (45,46).
There is much yet to learn about EBV and KSHV; these 
two viruses have been extensively investigated in recent 
years, particularly using proteomic-based methods. These 
technologies have proved to be powerful tools in aiding our 
understanding of these important pathogens and may help 
elucidate new aspects of viral biology as they become more 
widely used.
2. Approaches to proteomics
Gel electrophoresis-based methods. The first attempts to 
analyse the proteome occurred in the early 1970s, making 
use of a new technique known as polyacrylamide gel electro-
phoresis (PAGE) (47). Since then, there have been a number 
of developments in proteomic techniques and a VLJQLÀFDQW 
increase in their utility. In this review, we provide a brief 
overview of the most commonly used proteomic approaches.
Gel-based methods belong to the most established tech-
niques in proteomics and remain the preferred choice for 
separation and semi-quantitative identification of various 
7DEOH,7KHKXPDQƢKHUSHVYLUXVHVDQGWKHLUDVVRFLDWHGGLV-
eases.
 Associated
Virus malignancy Name
EBV B-cell lymphoma Burkitt's lymphoma
  Hodgkin's lymphoma
  PTLD
 T-cell lymphoma Extranodal natural killer/
  T-cell lymphoma
 Carcinoma NPC
  Gastric carcinoma
KSHV Sarcoma KS
 B-cell lymphoma MCD
  PEL
EBV, Epstein-Barr virus; KSHV, Kaposi's sarcoma-associated her-
pesvirus; PTLD, post-transplant lymphoproliferative disease; NPC, 
nasopharyngeal carcinoma; KS, Kaposi's sarcoma; MCD, multicen-
tric Castleman's disease; PEL, primary effusion lymphoma.
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proteins. The most commonly used method is one-dimensional 
(1D)-PAGE, which may be used to separate denatured protein 
samples according to their molecular weight in a polyacryl-
amide gel (47). Although this technique is used for western 
blot analyses in numerous laboratories, it has limitations with UHJDUGVWRLGHQWLÀFDWLRQRIVLQJOHSURWHLQVZLWKLQODUJHSURWHLQ
mixtures. Proteins of the same mass are detected at the same 
position in the gel, leading to a mixed signal.
This problem may be overcome by using two-dimensional 
(2D)-PAGE. With this method, the proteins are separated by WKHLULVRHOHFWULFSRLQWDORQJDS+JUDGLHQWLQWKHÀUVWGLPHQVLRQ
a process termed isoelectric focusing (48). This is followed by 
separation according to molecular mass. Due to the introduc-
tion of the second dimension, separation of 10,000 proteins 
is possible (49). Furthermore, recent developments in protein VWDLQLQJWHFKQLTXHVVXFKDVWKHLQWURGXFWLRQRIÁXRUHVFHQW
dyes, have allowed not only a sensitivity of detection in the 
femtomolar range, but also widened the linear dynamic range 
by approximately three orders of magnitude (50-55). However, 
direct comparison between different protein samples has 
always been a weak point, as separate gels must be run for 
each sample and methodical errors may intervene with the 
obtained results. This has been overcome by introducing Áuo-
rescence 2D difference gel electrophoresis (2D-DIGE), which 
allows comparison of protein samples in one gel (56,57). In 
this approach, the respective protein mixes are labelled with 
cyanine dyes (CyDyes), which bind covalently to the e-amino 
group of the lysine residues of the proteins. Currently, three 
different CyDyes are available, namely, Cy2, Cy3 and Cy5, 
which mayEHVHSDUDWHO\GHWHFWHG6SHFLÀFVRIWZDUHHJ, 
DeCyder, has been developed to help analyse the gel images. 
Although this technique is highly sensitive, its power is 
limited due to potential inconsistent labelling of proteins (56). 
Furthermore, 2D-DIGE does not overcome the limitations of 
2D-PAGE, as all the proteins must be in a molecular weight 
range between 5 and 150 kDa and a pH range of 3.5-10 in 
order to be detected (56,58). Proteins that are successfully 
separated by 2D- or 1D-PAGE, mayEHIXUWKHUGHÀQHGE\
mass spectrometry (MS).
MS-based methods. Over the last three decades, developments 
in liquid chromatography (LC), MS and protein labelling, e.g., 
the introduction of electrospray ionisation (ESI) and stable 
isotope labelling by amino acids in cell culture (SILAC), 
have enabled the establishment of shotgun proteomics. MS is 
currentlyFRPPRQO\XVHGIRUDFFXUDWHSHSWLGHLGHQWLÀFDWLRQ
and quantification. Quantitative proteomics strategies rely RQUHODWLYHTXDQWLÀFDWLRQFRPSDULQJWKHOHYHOVRILQGLYLGXDOSHSWLGHVLGHQWLÀHGIURPRQHRUPRUHH[SHULPHQWDOVDPSOHVWR
those levels from an untreated control sample. This provides 
an invaluable and powerful tool for global analysis of protein 
composition; however, it is important to highlight that the 
proteomic coverage of the genome remains a major technical 
challenge, as only ~10% of the proteins present in the sample DUHLGHQWLÀHGDQGHYHQIHZHUDUHTXDQWLÀHG06EDVHG
proteomic approaches may be used to identify and quantify 
proteins from a whole-cell lysate, an isolated organelle/region 
of a cell population (e.g., nuclear envelope), or a particular tissue RURUJDQLVP$VSUHYLRXVO\DOOXGHGWRIXUWKHUSURWHLQSXULÀFD-
tion may be achieved by means of LC or gel electrophoresis. 
These strategies allow the removal of high-abundance proteins, 
which would otherwise mask low-abundance proteins, while 
also reducing sample complexity for increased peptide iden-
tification and quantification. Following purification, equal 
amounts of protein from each of the samples are proteolyti-
cally digested into peptides, often using trypsin. The digested 
peptides are separated and ionized by LC coupled to ESI and 
are then subjected to tandem MS (MS/MS). The fractions XQGHUJRDÀUVWURXQGRI0606, in which the mass-to-charge UDWLRPŻ]RIDOOLRQLVHGSHSWLGHVLVPHDVXUHGJHQHUDWLQJD
precursor ion spectrum. The relative intensity of each spec-
trum peak correlates proportionally to peptide concentration, DOORZLQJUHODWLYHTXDQWLÀFDWLRQDFURVVGLIIHUHQWH[SHULPHQWDO
conditions. Individual peptide populations are then selected 
for collision-induced dissociation (CID) with an inert gas and DVHFRQGURXQGRI0606GHWHUPLQHVWKHPŻ]RIWKHSHSWLGH
fragments generating a CID spectrum. This spectrum is then 
compared with a theoretical database produced via an in silico GLJHVWIRUSHSWLGHLGHQWLÀFDWLRQFig. 1) (60,61). The majority 
of global proteomic analyses across different experimental 
conditions are currently performed using stable isotope label-
ling, mass tag labelling or label-free approaches (62).
SILAC. 6,/$&DVÀUVWGHVFULEHGE\2QJet al (63), is an in vivo 
metabolic labelling technique, enabling the incorporation of 
different atomic isotopes into proteins as they are being synthe-
sised in the living cell. SILAC is routinely performed using cell 
culture systems, but it has also been applied to simple organ-
isms (e.g., C. elegans or Drosophila melanogaster) (64) and 
even mice (65). Stable (non-radioactive) naturally occurring LVRWRSHVDUHYDULDQWVRIDVSHFLÀFFKHPLFDOHOHPHQWFRPPRQO\
H, C, N and O), which contain the same number of protons 
but different numbers of neutrons in each atomic nucleus. 
Isotopes have identical chemical properties, reducing the risk 
of introducing experimental bias between differently labelled 
samples, but the isotopes have different masses; therefore, they 
areHDVLO\LGHQWLÀHGE\06The cells are cultured in growth 
medium with specifically labelled amino acids containing 
either a light isotope (e.g., 12C-lysine and/or 12C-arginine) or a 
heavy isotope (e.g., 13&O\VLQHDQGŻRU13C-arginine). 13C has an 
extra neutron compared to 12C, which gives 13C an increment in 
its mass number of 1 Da. The substitution of light 12C-arginine 
with heavy 13C-arginine results in a 6-Da increment in the 
mass spectrum of a peptide containing one arginine, as a 
single arginine residue contains six carbons. Trypsin cleaves 
lysine and arginine residues at the C-terminus; therefore, using 
these particular labelled amino acids ensures that all tryptic 
peptides (except for the C-terminal peptide) contain at least 
one labelled residue. For SILAC to work effectively, the cells 
must be grown in labelled growth medium for a number of 
passages in order to incorporate isotopes into the majority of 
the proteins. A very high rate of isotopic incorporation (>90%) 
is achieved in cells after 6-8 doublings (63). At this point, 
cells that have been differentially labelled undergo the desired 
treatment, for example, a viral infection. SILAC allows for a 
maximum of three different samples in a single mass spec run 
with the use of light (e.g., 12C-arginine and 12C-lysine; R0K0), 
medium (e.g., 13C-lysine and 2D lysine; R6K4) and heavy (e.g., 
13C 15N-arginine and 13C 15N lysine; R10K8) isotope-containing 
media. A major advantage of SILAC is that, once generated, 
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labelled and unlabelled samples are mixed in equal amounts 
into one pooled sample. This allows all the samples to be 
processed together, reducing the risk of external experimental 
error. Furthermore, due to its accuracy, SILAC is particularly 
suitable for revealing relatively small changes in protein levels RUSRVWWUDQVODWLRQDOPRGLÀFDWLRQV$OLPLWDWLRQRI6,/$&
however, is that certain cell lines may convert excess argi-
nine into proline and, therefore, titration of arginine into the 
medium may be required (66). In addition, SILAC may not be 
applicable to cells that are sensitive to changes in the medium 
composition. Combining SILAC with subcellular fractionation 
may further reduce sample complexity (Fig. 2).
,VRWRSHFRGHGDIÀQLW\WDJJLQJ,&$7LVREDULFWDJVIRUUHOD-WLYHDQGDEVROXWHTXDQWLÀFDWLRQL75$4DQGWDQGHPPDVVWDJJLQJ 707 ICAT was the first method involving the 
addition of isotopic tags to proteins for quantitative MS. This 
method was reported in 1999 by Gygi et al (67) and allows 
labelling of proteins present in any protein sample, including H[WUDFWVIURPWLVVXHVRUERG\ÁXLGV$VRSSRVHGWR6,/$&
Figure 1. Proteomic analysis by mass spectrometry (MS). Protein samples are frequently separated by one- and two-dimensional electrophoresis (1DE and 
2DE, respectively) to reduce sample complexity, prior to being subjected to liquid chromatography (LC) for further separation. The samples are then loaded 
onto the mass spectrometer for 2 rounds of detection and the output signal is used to quantify proteins in the sample.
Figure 2. Combining stable isotope labelling by amino acids in cell culture (SILAC) with subcellular fractionation. Cells are grown in SILAC media for 
6-8 doublings and are then fractionated into cytoplasmic and nuclear fractions. These fractions are then mixed 1:1 and sent for mass spectrometry (MS) 
analysis. This reduces sample complexity and minimizes the possibility of handling error. /&OLTXLGFKURPDWRJUDSK\PŻ]PDVVWRFKDUJHUDWLR
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labelling occurs in vitro following cell lysis. ICAT relies on the 
use of a reagent composed of three elements: a biotin molecule WRHQDEOHSXULÀFDWLRQRIWKHODEHOOHGSHSWLGHVZLWKWKHXVHRIDYLGLQRUVWUHSWDYLGLQDIÀQLW\FKURPDWRJUDSK\DOLQNHUJURXS, 
which contains stable isotopes (light or heavy); and a reactive 
iodoacetyl group,ZKLFKVSHFLÀFDOO\UHDFWVZLWKIUHHWKLROV
on cysteine residues. Following labelling, light and heavy 
samples are combined into one sample, which is subjected to SURWHRO\WLFGLJHVWLRQDIÀQLW\SXULÀFDWLRQDQG/&0606As 
labelling only occurs in proteins containing cysteine, which 
is a rare amino acid, ICAT inherently implies a considerable 
bias against proteins that lack or contain few cysteine residues; 
however, for the same reason, this technique is also advanta-
geous when one wishes to reduce complexity in the protein PL[WXUH$PRGLÀFDWLRQRI,&$7KDVEHHQGHYLVHGWRRYHUFRPH
this limitation, known as isotope-coded protein labelling (68), 
in which all free amino groups on intact proteins are isotopi-
cally labelled with either light or heavy tags, resulting in a 
higher proteomic coverage compared to ICAT.
Further techniques using tags of the same mass have also 
been developed for use in MS-based quantitative proteomics, 
most commonly known as iTRAQ and TMT. These tech-
niques enable examination of four, six or even eight different 
experimental conditions in a single MS experiment with the 
use of up to eight different isobaric mass tags. These tags 
are all of the same mass and consist of three components: 
an N-hydroxysuccinimide ester group, which reacts with 
primary amino groups; a mass tag (reporter) group; and 
a balance (carbonyl) group. The reporter group is based on 
N-methylpiperazine and contains a unique number of heavy 
13C and 15N substitutions. The masses added by each tag are 
compensated with balance groups of variable masses to make 
all tags equal in mass, meaning that the same protein from 
different samples will behave in the same manner during 
LC and MS1. Each experimental condition is enzymatically 
digested individually, the peptides are then tagged and the 
samples are pooled for LC-MS/MS analysis. Upon colli-
sion-induced dissociation, the mass tags are cleaved from the 
balance groups. During MS2, the intensity of the different tags DUHXVHGIRUUHODWLYHSHSWLGHTXDQWLÀFDWLRQ, whereas the peptide 
fragment ions are sequenced to determine protein identity. As 
isotopic labelling occurs after enzymatic digestion, the sample 
complexity is increased and more abundant proteins are over-UHSUHVHQWHGGXULQJ06LGHQWLÀFDWLRQL75$4DQG707
mayDOVREHXVHGIRUDEVROXWHTXDQWLÀFDWLRQ, in which the exact 
amount of a protein can be measured. The differences between 
these isobaric mass tags and the previously mentioned isotope-FRGHGDIÀQLW\WDJVDUHVKRZQLQFig. 3.
Label-free MS analysis. As the labelling of proteins is always 
limited by various factors, two label-free techniques have 
recently been developed for use in quantitative proteomics.
Spectral counting is simply based on counting mass spectra 
collected during a tandem MS run, as previous studies demon-
strated that the number of these mass spectra is proportional to 
the concentration of a given peptide and, therefore, its respective 
protein in the sample (58,70). Prior toLRQLVDWLRQDQG06Ż06
the peptides resulting from the initial protein trypsinisation are 
separated by LC. Elution of highly concentrated peptides into WKH06Ż06LRQLVDWLRQFKDPEHURFFXUVRYHUDORQJHUSHULRG
compared to the elution of peptides with lower concentrations; 
therefore, more spectra of the more concentrated peptides may 
be acquired compared to the less concentrated peptides (70). 
Although modern LC systems are capable of very accurate 
separation, there is always the possibility of co-eluting peptides 
when analysing complex protein samples (58). This has resulted 
in critical discussion regarding this label-free method, particu-
larly as no other physicochemical properties of the individual 
peptides are measured (71). However, there have been recent 
developments to improve spectral counting and moving from UHODWLYHTXDQWLÀFDWLRQWRDEVROXWHSURWHLQPHDVXUHPHQW7KH
normalised spectral abundance factor (NSAF), the distributed 
NSAF and the normalised spectral index take into account 
not only the number of spectra, but also peptide count, protein 
length, sample-to-sample variation for replicate analyses, 
fragment-ion intensity and the distribution of spectral counts 
of peptides shared by different proteins (72-74). The absolute 
protein expression aims for absolute protein measurement 
by calculating the proportionality of expected peptides after 
trypsinisation and the observed peptides for a given protein DIWHU06Ż06
Measurement of chromatographic peak areas (or MS signal 
intensities) is the second method used for label-free quantitative 
proteomics. The peptides are separated by LC according to their 
Figure 3. Isobaric mass tags and iVRWRSHFRGHGDIÀQLW\WDJV,VREDULFPDVVWDJVFRQWDLQDYDULDEOHPDVVUHSRUWHUIRULGHQWLÀFDWLRQRIVDPSOHDQGDUHEDODQFHG
to equal weights, resulting in identical behavior during the liquid chromatographyVHSDUDWLRQVWDJH,VRWRSHFRGHGDIÀQLW\WDJVDOVRFRQWDLQDYDULDEOHPDVVUHSRUWHUNQRZQDVDOLQNHUIRUVDPSOHLGHQWLÀFDWLRQDQGFRQWDLQDbLRWLQPROHFXOHWRDOORZDYLGLQDIÀQLW\SXULÀFDWLRQRIWDJJHGSHSWLGHV%RWKWDJVDUHMRLQHGWRVSHFLÀFDPLQRDFLGUHVLGXHVLQWDJJHGSHSWLGHVWKURXJKDUHDFWLYHWHUPLQXV
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physical properties, e.g., charge or hydrophobicity, followed by 
ionisation and detection of peptide precursor ions in a mass VSHFWURPHWHU(YHU\SUHFXUVRULRQJHQHUDWHVDVSHFLÀFPRQR
isotopic peak, the intensity of which may be shown as function 
of the LC retention time in an extracted ion chromatogram. The 
chromatographic peak areas for each peptide, determined by 
the area under the curve, correlate with the abundance of the UHVSHFWLYHSHSWLGH7KHUHIRUHDUHODWLYHTXDQWLÀFDWLRQEHWZHHQ
different protein samples is possible (76-78). However, this 
requires a high level of reproducibility between the different 
samples (71,78). Moreover, due to identifying and focusing on VSHFLÀFSUHFXUVRULRQVDWDQHDUO\VWDJHWKHUHPD\EHDUHGXF-
tion in the peptides sequenced during MS/MS (79). To overcome 
this, two separate analyses, one LC-MS and one LC-MS/MS, 
may be performed for each sample. Nevertheless, newer and 
faster mass spectrometers are able to collect data for MS as well 
as MS/MS scans at a satisfying rate (71,79).
Although label-free is currently the least accurate 
proteomic method, it is worth considering, as it displays 
distinct advantages. First, the money- and time-consuming 
step of introducing labels into proteins is not necessary, which 
also leads to a reduction in experimental stages. Furthermore, 
although multiplexing is not available for label-free samples, 
there is no limit for parallel experiments if all the stages of 
sample preparation and analyses are reproducible. Finally, 
label-free quantifications exhibit a higher dynamic range 
compared to stable isotope labelling. The merits of spectral 
counting, in particular, have been demonstrated when seeking 
large changes in protein levels compared to SILAC-labelled 
samples (70,71,80).
There are several factors to be considered when selecting 
a particular method (Fig. 4), but often different approaches 
yield comparable results; therefore, most consideration should 
potentially be given to the ease of application and how well 
equipped a lab is to attempt any given approach.
Proteomic methodologies have been demonstrated to be 
useful in a wide range of biological investigations, including 
numerous studies of interactions between virus and host 
proteomes. There are a number of examples of Ƣ-herpesvirus 
studies that have utilised these approaches, which have helped 
elucidate several aspects of their biology.
3. Understanding Ƣ-herpesviruses through proteomics
EBV is an extremely successful oncovirus, infecting a predicted 
90% of the population; however, very few infected individuals 
actually develop neoplasia. This demonstrates the ability 
of EBV to limit its oncogenic potential, despite expressing 
multiple proteins able to immortalise cells in vitro. It is not 
surprising, therefore, that various studies have demonstrated 
that EBV exerts a VLJQLÀFDQW effect on the cellular transcrip-
tome. Less attention has been given to the effect of EBV of the 
cellular proteome; however, this is an important consideration, 
as changes in mRNA abundance do not always translate into 
alterations at the protein level. Hence, a thorough investigation 
of the effect of EBV on the cellular proteome is warranted.
As the most recently discovered human herpesvirus, our 
knowledge of KSHV is behind that of other, more characterised 
viruses, such as EBV. However, over the last decade, several 
investigations into KSHV biology have been performed, 
)LJXUH6HYHUDODSSURDFKHVWRSURWHRPLFVWXGLHV7KLVÁRZFKDUWVXJJHVWVZKLFKSURWHRPLFWHFKQLTXHWRXVHEDVHGRQWKHSURSHUWLHVRIWKHVDPSOHEHLQJ
analysed. 1D, one-dimensional; 2D, two-dimensional; PAGE, polyacrylamide gel electrophoresis; SILAC, stable isotope labelling by amino acids in cell FXOWXUH,&$7LVRWRSHFRGHGDIÀQLW\WDJJLQJL75$4LVREDULFWDJVIRUUHODWLYHDQGDEVROXWHTXDQWLÀFDWLRQ707WDQGHPPDVVWDJJLQJDIGE, difference gel 
electrophoresis.
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utilising advanced proteomic-based technologies, which have UHVXOWHGLQVLJQLÀFDQWadvances in our understanding of this 
virus. As with EBV, there remains much to learn regarding 
KSHV biology and large systems biology approaches, such as 
proteomic-based studies, may play a major role in elucidating 
the intricacies of these two complicated pathogens.
Proteomic analysis of Ƣ-herpesvirus virions. Early analyses of 
viral proteomes often focus on the composition of the mature 
viral particle, as the proteins found within are often instru-
mental to a successful infection. As with all herpesviruses, 
EBV and KSHV have complex virions, constructed of an inner 
nucleoprotein core, a viral capsid, an inner tegument layer and DOLSLGHQYHORSH6XUSULVLQJO\GHVSLWHEHLQJWKHÀUVWWUXH
human oncovirus to be discovered, only a single study has 
used proteomic analyses to comprehensively study EBV virion 
composition (82). In that study, the EBV lytic cycle was induced 
from latently infected B cells by the ectopic expression of the 
EBV lytic switch protein, Zta. Mature virus particles were SXULÀHGXVLQJGHQVLW\JUDGLHQWVGHHQYHORSHGDQGVXEMHFWHGWR LQJHO WU\SVLQGLJHVWLRQ DQG/&06Ż067KLV DQDO\VLV
largely demonstrated that EBV virion morphogenesis follows 
that of other herpesviruses, such as the model herpesvirus, 
herpes simplex virus (HSV). ICAT was also used to determine 
how likely a protein was to be associated with the envelope 
or the EBV capsid. In this example, 12C ‘light’ labelled envel-
oped virions were mixed with 13C ‘heavy’ labelled virions 
that had been treated with detergent to remove the envelope. 
Following normalisation between samples on the major capsid 
protein, it was observed that several cellular proteins were 
major components of mature EBV virions, including ơ-actin RQHRIWKHPRVWDEXQGDQWWHJXPHQWSURWHLQVFRÀOLQWXEXOLQ
heat shock protein (Hsp)70, Hsp90 and other actin-associated 
proteins (ARPs),VXFKDVSURÀOLQH]ULQUDGL[LQPRHVLQand Ơ-actinin. Hsp70, Ơ-tubulin, ơ-tubulin and actin were shown to 
be tightly associated with capsids, suggesting that they may be 
involved in stabilising the capsids or that they may be required 
immediately after de-envelopment during de novo infections. 
Additional functions for the cellular proteins may include 
EBV virion morphogenesis and egress.
Initial determinations of the KSHV virion components 
were performed in a similar manner, subjecting mature virions SXULÀHGE\GHQVLW\JUDGLHQWWR'JHOHOHFWURSKRUHVLVLQJHO
tryptic digest and MS (83). In total, 24 proteins of structural, 
regulatory and signalling roles were identified, including 
5 capsid proteins, 8 tegument proteins, 8 glycoproteins found 
within the lipid envelope and a further 3 proteins associated 
with the virion. Of note, severalRIWKHLGHQWLÀHGSURWHLQVZHUH
of cellular origin, including a number of proteins also found in 
EBV virions, such as ơ-actin and the ARPs ezrin and moesin. 
The roles of these proteins in the viral particle have not yet 
been elucidated; however, their presence suggests that they 
are required for virion stability or during the early stages of 
infection.7KHFKDSHURQHV+VSDQG+VFLGHQWLÀHGLQWKHYLULRQVRIDZLGHUDQJHRIYLUDOIDPLOLHVZHUHDOVRLGHQWLÀHGLQWKH
tegument of KSHV. These proteins have been shown to play 
numerous roles in viral processes, ranging from relocalization 
of key viral factors to aiding in the reverse transcription of 
retroviral genomes. Furthermore, the KSHV lytic reactivator 
protein replication and transcription activator (RTA) (84) was LGHQWLÀHGDVDFRPSRQHQWRIWKH.6+9WHJXPHQWVXJJHVWLQJ
that RTA drives a round of lytic gene expression immediately 
after infection. These studies demonstrated WKHHIÀFDF\RI
using reduced-complexity samples with MS-based proteomics 
to identify a subset of viral and cellular proteins involved in 
different aspects of viral biology.
Elucidating the effects of fully competent Ƣ-herpesvirus 
infection through proteomics. In an attempt to gain under-
standing of EBV pathogenesis, Alsayed et al (85) performed 
a proteomic analysis of PTLD tissues from solid organ 
transplant patients using a protein microarray technique. 
The proteins that were dysregulated included proteins of 
the phosphoinositide 3-kinase (PI3K)/mammalian target 
of rapamycin, nuclear factor-țB and Hsp90 pathways, all of 
which are entirely consistent with the latency III gene expres-VLRQSURÀOHLQ37/',QWHUHVWLQJO\ZKHQVSHFLÀFLQKLELWRUVRI
these proteins were then tested in EBV+ and EBV- cell lines, WKH\ZHUHIRXQGWREHVSHFLÀFDOO\F\WRWR[LFLQWKH(%9+ lines. 
Indeed, it was recently demonstrated that the Hsp90 inhibi-
tors geldanamycin, 17-allylamino-17-demethoxygeldanamycin 
and 17-dimethylaminoethylamino-17-demethoxygeldana-
mycinVSHFLÀFDOO\GHFUHDVHG(%1$WUDQVODWLRQOHDGLQJWR
cytotoxicity of EBV+FHOOVDQGVLJQLÀFDQWO\LQKLELWLQJO\PSKR-
proliferative disease in VHYHUHFRPELQHGLPPXQRGHÀFLHQF\ 
mice (86,87). Together, these early results highlighted the 
value of proteomics in identifying novel therapeutic targets.
Proteomic analyses have also been applied in order to 
understand how the human Ƣ-herpesviruses manipulate inter-
cellular communication. In addition to the secretion of soluble 
factors that promote the establishment of latency (or indeed, WXPRXULJHQHVLVYLUDOO\LQIHFWHGFHOOVDOVRUHOHDVHPRGLÀHG
exosomes. These are a class of endosomal-derived membrane 
microvesicles from multivesicular bodies that, after release, 
may fuse with recipient cells, into which they release their 
contents and modulate biological activities. Although this is 
a normal physiological process, there is evidence suggesting 
that altered exosome function may be pathogenic, particularly 
during malignancy. It was demonstrated that EBV-infected 
cells release exosomes containing virally-encoded miRNAs 
and proteins and that these factors are able to alter target 
cell function (88-90). For example, EBV's major oncoprotein 
LMP1 was highly enriched in exosomes secreted from naso-
pharyngeal carcinoma (NPC) cells and the transfer of these to 
recipient cells activated several LMP1-associated signalling 
cascades,LQFOXGLQJ3,.Ż$.7DQGmitogen-activated protein 
kinaseŻextracellular signal-regulated kinase (91). LMP1 has DOVREHHQLGHQWLÀHGLQ%-cell-secreted exosomes and this may 
be important for inducing proliferation and B-cell survival, a 
crucial step in the establishment of EBV latency and colonisa-
tion.
However, there remains the major question whether viral 
infections dictate the composition of secreted exosomes. This 
was recently addressed by Meckes et al (92) using a combina-
tion of MS and 2D-DIGE to determine the repertoire of proteins 
in EBV+, KSHV+ and dually infected cell line exosomes, 
compared to non-infected counterparts. In that study, a total RISURWHLQVZHUHLGHQWLÀHGIURPDOOH[RVRPHSUHSDUDWLRQV
and 449 of these proteins were common among infected and 
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non-infected cell lines. Therefore, several hundred exosome 
proteins were enriched as a result of Ƣ-herpesvirus infections. 
Some of these proteins were specific to EBV (n=93) and 
others to KSHV (n=22), suggesting that these different viruses 
manipulate the exosome proteome in diverse ways, possibly 
in order to optimally promote their particular life cycles. 
Furthermore, a 2D-DIGE, coupled with a spectral count-based 
quantitative proteomic approach, was employed to compare 
the exosomes of LMP1+ and LMP1- cells, confirming that 
several of the alterations in the EBV-associated exosome cargo 
were due to LMP1. Moreover, the pathway analysis revealed 
that both EBV- and KSHV-associated exosome components 
largely affect similar cellular pathways, although KSHV 
exosomes were enriched in proteins involved in cellular 
metabolism, whereas EBV-associated exosomes were geared 
towards cellular signalling pathways.
The abovementioned f indings demonstrate that 
proteomic-based research is able to identify multiple protein 
pathways that are altered by related viruses and put these 
into the context of a viral infection. However, a potential 
caveat that exists in a majority studies regarding the human Ƣ-herpesviruses is the lack of isogenic virus-negative counter-
parts to rule out the possibility that some differences are purely 
cell type-VSHFLÀF'HVSLWHWKLVcaveat, however, these studies 
enhance our understanding of how KSHV and EBV manipu-
late the tumour microenvironment and provide potential new 
avenues for therapeutic intervention. Interestingly, several of WKHSURWHLQVLGHQWLÀHGLQPDWXUHƢ-herpesvirus virions have 
also been detected in their exosomes (e.g., actin and ezrin), 
signifying the possibility that virally induced exosomes may 
mimic viral infection. If this is true, the extent to which it may EHQHÀWYLUXVFRORQLVDWLRQUHPDLQVWREHdetermined. The next 
challenge will be to elucidate how viruses dictate exosome 
proteomes and how this translates in vivo.
Investigating the interactions and effects of specific viral 
factors. Proteomic approaches have also been used to inves-
tigate the function of individual viral proteins. The EBNA2 
protein is considered to be the master transcriptional activator, 
switching on the expression of all of EBV's immortalising 
genes, as well as various cellular genes known to be critical 
for EBV infection, such as CD23. In an attempt to identify 
proteins altered due to EBNA2 expression, 2D-PAGE was 
applied to a protein sample from a conditionally immortalised 
B-cell line, in which EBNA2 is activated by translocation 
to the nucleus, due to the addition of oestrogen (93). In that 
study, EBNA2 target proteins and the proteins that were 
induced during primary B-cell infection were shown to 
correlate, highlighting the major role of EBNA2 during the 
establishment of latency and B-cell immortalisation. A total 
of 20 GLIIHUHQWLDOO\H[SUHVVHGSURWHLQVZHUHLGHQWLÀHG12 of 
which were upregulated, including the protein synthesis and 
degradation factors eIF5a, P0, PA28Ƣ and ubiquitin thioles-
terase L3, as well as two proteins involved in nucleotide 
metabolism, Nm23-H1 and pyrophosphatase. Some of the best FKDUDFWHULVHG(%1$UHVSRQVLYHSURWHLQVZHUHQRWLGHQWLÀHG
however, suggesting incomplete coverage due to the nature of 
the proteomic approach employed.
Similarly, the effect of individual KSHV protein expres-
sion has been investigated using a gel-based approach. 
2D-DIGE was successfully utilised to analyse the protein 
content of endothelial cells expressing the KSHV vFLIP 
protein (94). This study identified 14 proteins upregulated 
upon vFLIP expression, the most highly upregulated of which 
was manganese superoxide dismutase (MnSOD). Interestingly, 
this is an antiapoptotic enzyme that has also been shown 
to be upregulated in KSHV-infected cells. Importantly, SUHYLRXVWUDQVFULSWRPHDQDO\VHVDOVRLGHQWLÀHG0Q62'WREH
upregulated at the RNA level, demonstrating the possibility 
of combining proteomics and transcriptomics approaches to 
validate and enhance results (94,95) (see Section 4).
Another proteomic-based study of EBV investigated the 
transformation potential of the EBV LMP1 oncoprotein in 
NPC cell lines (96). In that study, a total of 250 proteins were 
detected by iTRAQ-based analysis, 12 of which were shown to 
be differentially expressed (although proteins that changed as 
little as 1.33-fold were also considered), including 6 proteins 
involved in signal transduction: voltage-dependent anion 
channel 1, S100-A2, hormone-induced protein-70, ubiquitin, 
tumour protein translationally-controlled 1-like protein and 
4F2hc, as well as 3 proteins pertaining to cyctoskeleton forma-
tion: keratin-75, TB8 and dynein light chain 1.
The first SILAC-based study designed to investigate a 
small number of changes in specific subcellular compart-
ments utilised the expression of the KSHV K5 protein (97). 
Modulation of the host immune response, particularly via 
major histocompatibility complex (MHC) class I molecules, 
is a common trait amongst pathogens. The KSHV-encoded 
K3 and K5 proteins, which function as membrane-bound 
RING-CH ubiquitin ligases and target MHC I for lysosomal 
degradation, are homologues of the K3 family of viral 
immune modulators. Importantly, other viral downregulators 
of MHC I are also known to target additional transmembrane 
proteins pertaining to different cellular pathways. In order to 
identify any novel K5 targets, plasma membrane, endoplasmic 
reticulum (ER) and Golgi apparatus were isolated from 
labelled control cells or cells expressing K5. In addition to 
the expected downregulation of MHC I, 3 novel peptides were 
found to be downregulated in the plasma membrane of cells 
expressing K5: activated leukocyte cell adhesion molecule, 
bone marrow stromal cell antigen 2 (BST-2) and syntaxin-4. 7KHLGHQWLÀFDWLRQRI WKHVHSURWHLQVPDUNHGDSUHFHGHQW LQ
SILAC proteomics, as it demonstrated a new approach for 
identifying additional targets of viral proteins. BST-2 (also 
known as tetherin) is of particular interest, as this protein ZDVÀUVWLGHQWLÀHGDVDKRVWUHVWULFWLRQIDFWRUWKDWSUHYHQWVWKH
release of budding retroviruses from the plasma membrane. 
HIV is able to counteract BST-2 via its auxiliary protein, viral 
protein unique, by co-opting a cellular ubiquitin ligase, ơTrCP, UHVXOWLQJLQ%67GHJUDGDWLRQ6XEVHTXHQWVWXGLHVFRQÀUPHG
that BST-2 is indeed a ERQDÀGH target of K5, although it was 
shown to be subjected to proteasomal degradation as it left 
the ER, rather than being degraded at the plasma membrane 
by the lysosome (as is true of other K5 targets). Therefore, 
similar to HIV, KSHV has also developed a mechanism of 
circumventing BST-2 function, although this virus has evolved 
its own specialised ubiquitin ligase, namely K5.
MS-based proteomics have also been used to identify 
cellular proteins binding to the terminal repeat regions (TRs) 
of the KSHV genome during latency. KSHV TRs contain the 
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latent origin of viral replication and play a major role in the 
maintenance and spread of the viral episome among dividing 
cells. In order to further characterise these important regulatory HOHPHQWV75VHTXHQFHVZHUHXVHGWRDIÀQLW\FDSWXUHSURWHLQV
from KSHV-positive cell lysates, which were subjected to 
MS-based proteomic analysis (98). In total, 123 proteins were 
found to bind the TRs of KSHV and further analysis on 4 of 
these proteins, namely ataxia telangiectasia and Rad3-related 
protein, transcription activator BRG1, nucleophosmin 1 and 
poly(ADP-ribose) polymerase 1, demonstrated that they asso-
ciate with the KSHV-encoded LANA. This suggested that 
proteins binding TR sequences may play a role in viral latency.
Furthermore, by employing affinity capture methods 
coupled to 1D-PAGE and MS, glutathione S-transferase-tagged 
N- and C-terminal regions of LANA were used to capture and 
identify protein interaction partners of LANA (99). Several 
proteins were found to bind to the N-terminus (n=53) and 
the C-terminus (n=56) and functional analysis of the protein JURXSVLGHQWLÀHGGLIIHUHQWFDWHJRULHVLQFOXGLQJ$73DVHV
ribonucleoproteins and cytoskeletal proteins. Whilst the 
majority of these novel interactions are yet to be fully charac-
terised, most of the proteins that bound LANA were found to 
be transcription factors and DNA-binding proteins, suggesting 
that LANA plays an important role in transcriptional control.
More recently, our laboratory has undertaken SILAC-based 
proteomics to elucidate the effects of the essential KSHV mRNA 
processing protein, ORF57 (100,101), on cellular pathways. To 
this end, an inducible HEK293-based system expressing ORF57 
was utilised. To maximise the data obtained from the study, 
cellular fractionation was performed to separate the major 
cellular compartments where ORF57 is known to be present: 
the cytoplasm, nucleoplasm and nucleoli (102). Predictably, as 
ORF57 is a known viral RNA processing protein, its expression 
led to an enrichment of proteins involved in RNA processing, 51$SRVWWUDQVFULSWLRQDOPRGLÀFDWLRQDQGJHQHH[SUHVVLRQ
particularly in the nucleolar fraction, where ORF57 is highly DEXQGDQW,PSRUWDQWO\WKHDQDO\VLVDOVRLGHQWLÀHGDQ
enrichment in DNA repair proteins that led to the discovery of 
a novel role for ORF57 in genome instability (105). That study 
highlighted the VLJQLÀFDQFH of large-scale proteomics studies 
for identifying novel proteins or cellular pathways of interest. 
Moreover, cellular fractionation and isolation of cellular 
compartments or organelles linked to SILAC proteomics will VXEVWDQWLDOO\LQFUHDVHWKHÁH[LELOLW\RIWKLVW\SHRIDSSURDFK
Combining protein immunoprecipitation with mass 
spec-based quantitative proteomics provides another way to 
reduce sample complexity and gain greater insight into the 
intricacies of viral infection. Malik-Soni and Frappier (106) 
have used this method to elucidate the interaction partners 
of the EBV EBNA1 protein in EBV-positive and -negative 
NPC cell lines. In that study, EBNA1 was found to have very 
similar interactomes in the two different cell backgrounds and WKHVHLQWHUDFWLRQSURÀOHVODUJHO\DJUHHGZLWKSUHYLRXVVWXGLHV
using HEK 293T cells. Furthermore, the EBNA1 interaction 
partners in AGS cells infected with latent EBV were highly 
similar to those in lytically infected cells, demonstrating that 
several of the EBNA1-host protein interactions occur indepen-
dent of EBV infection. Of note, EBNA1 was also shown to 
associate with numerous heterogeneous nuclear ribonucleo-
proteins and the La protein, which associated with the 3' ends 
of newly synthesized small RNAs and had previously been 
shown to bind EBV EBERs (107). The interaction between La 
and EBNA1 only occurred in the context of full EBV infection 
and was ablated by RNase treatment, suggesting this interac-
tion is bridged by EBERs. EBNA1 also appeared to interact 
with the nucleolar protein B23 (nucleophosmin), a protein that 
frequently plays a role in infection with other viruses, such as 
KSHV and HIV-1 (98,108).
Other large-scale studies have also added to our knowl-
edge of the KSHV proteome, although not strictly through a 
proteomic approach. For example, a large study was performed 
by Sander et al (109) with the aim to map the subcellular 
localisation of every KSHV protein in HeLa cells in order to 
elucidate potential roles of proteins within the context of the 
viral infection with regard to their location.
Greater understanding of a viral proteome may also be used 
to create novel diagnostic tools. Recently, a 96-well format 
multiplex bead-based assay was used to analyse the serological 
response of 2 groups of individuals previously diagnosed with 
KSHV-associated malignancies (n=36) or with a low likeli-
hood of KSHV infection (n=43) to 73 different recombinant 
proteins encompassing most of the KSHV proteome (110). 
Historically, the KSHV ORF73 and K8.1 proteins have been 
used to determine whether an individual is infected; however, 
the patterns of reactivity in those infected with KSHV were 
found to be highly variable. That study identified 6 more 
viral proteins that may be tested for to distinguish between 
KSHV-positive and -negative individuals, providing a more 
powerful and reliable tool for clinical KSHV serodiagnosis.
This selection of proteomic-based research demonstrates 
the power of the numerous techniques that have been devel-RSHGLQWKLVÀHOGCombining proteomic techniques with other 
large-scale systems biology approaches may provide an even 
greater insight into the various processes occurring within 
populations.
4. Combining OMICS approaches to maximise function
It is becoming increasingly apparent that utilising multiple 
high-throughput systems techniques can create a synergy, 
enabling greater insight into more biological processes, rather WKDQE\UHO\LQJRQDQLQGLYLGXDO WHFKQLTXH$VWKHÀHOGRI
large-scale proteomics is still in its infancy, it is likely that 
the full potential of combining OMICS approaches has not 
yet been realised, although there are numerous published 
examples of groups combining two or more methods to answer 
newly arising questions.
Currently, the majority of proteomic-based studies focus 
on model organisms, for which there exists a database of 
encoded proteins. A recently developed approach, known as 
Proteomics Informed by Transcriptomics (PIT), combines deep 
sequencing-based transcriptomics (RNA-seq) with MS-based 
quantitative proteomics (111). PIT allows the interpretation of 
the proteomes of multiple species in the same sample, or of 
species without a complete reference genome, using the tran-
scriptome data to reveal any proteins that may be present. This 
approach may also be used to identify changes in mRNA levels WKDWDUHQRWUHÁHFWHGDWWKHSURWHLQOHYHODOORZLQJWKHLGHQWL-ÀFDWLRQRISRWHQWLDOSRVWWUDQVFULSWLRQDOGHJUDGDWLRQWDUJHWV
Furthermore, combining these different OMICS procedures 
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allows researchers to overcome the limitations of an individual 
technique, such as incomplete coverage of the transciptome, 
due to high mRNA turnover rate, or of the proteome, due to the LVVXHVSUHYLRXVO\PHQWLRQHGZLWK/&06Ż06DQDO\VLV
Other attempts to apply large-scale OMICS techniques 
to non-model species rely on the sequencing and annotation 
of a novel reference genome. The initial interpretation of 
a novel genome is often heavily guided by using sequence 
homology to closely related species and in silico predictions 
of open reading frames. This commonly results in incomplete 
genome annotations, often ignoring non-canonical elements, 
such as transcription start sites or genomic regions that lack 
sequence homology to other previously characterised genes. 
Indeed, some of the most interesting aspects of KSHV 
and EBV biology involve EBERs, EBNA1 and KSHV 
LANA, all of which could be missed using these traditional 
methods of genome annotation. However, the combination of /&06Ż06EDVHGSURWHRPLFVZLWKFXVWRPWLOLQJDUUD\VKDVÀOOHGLQDQXPEHURIJDSVLQWKHYLUDOJHQRPHDQGLGHQWLÀHG
several novel genes (112). That previous study demonstrated 
that combining two or more high-throughput approaches may 
compensate for the limitations of each individual approach 
and further demonstrated that combining transcriptome and 
proteome data may also provide some insight into the stability 
of the detected transcripts and proteins.$QRWKHUUHFHQWO\LGHQWLÀHGJDSLQWKHYLUDOJHQRPHDQQR-
tations came in the form of small non-coding RNAs, named 
miRNAs, which are primarily involved in the repression of 
translation and have been hailed as one of the most impor-
tant breakthroughs in biology (113,114). The identification 
and characterisation of functional miRNAs has proved to be DGLIÀFXOWHQGHDYRXULQUHFHQW\HDUVZLWKQXPHURXVSUHGLF-
tive algorithms being designed to elucidate target mRNA 
molecules. A number of these algorithms, however, rely on 
assumptions about miRNAs binding to target sequences at the 
3' end of the target mRNAs, despite other mechanisms having 
been demonstrated (115). Even when this simplistic approach 
is applied, it often results in a high rate of false-positives and 
predicts a large list of potential targets that could not feasibly 
be experimentally validated. Using deep sequencing, aber-UDQWO\H[SUHVVHGPL51$VKDYHEHHQLGHQWLÀHGLQRVWHRSHWURVLVSDWLHQWVDQGSURSRVHGWDUJHWVZHUHLGHQWLÀHGE\WKHLUDOWHUHG
protein expression using iTRAQ proteomics (116). This 
approach led to the identification of 96 novel miRNAs in 
the osteopetrosis samples and also provided a useful method IRULGHQWLI\LQJPL51$WDUJHWSDLUVZLWKJUHDWHUFRQÀGHQFH
compared to that which could be achieved by relying on predic-
tive algorithms alone. A similar approach has also been used 
to identify targets of several viral miRNAs encoded by KSHV, 
whereby pulsed SILAC was employed to identify host cell genes 
repressed at the protein level upon expression of individual 
viral miRNAs (117). While it may be possible to identify some 
miRNA-mRNA target pairs using deep sequencing alone, this 
may result in only identifying degraded mRNA targets and not 
those for which translation is inhibited by other means (118).
Until recently, ~32-39% of the predicted genes on chromo-VRPHDORQHODFNHGDQ\SURWHLQLGHQWLÀFDWLRQDFFRUGLQJWRWKH
Chinese Human Chromosome Proteome Consortium (119), 
despite the publishing of a complete draft of the human 
genome over 10 years ago. In a recent effort to characterize 
all the missing proteins, an integrative OMICS approach was 
employed, combining MS-based proteomics, RNAseq and ULERVRPHSURÀOLQJ,DQHPHUJLQJWHFKQLTXHWKDWLGHQWLÀHVWKH
translation potential of mRNAs present in a sample (120). This 
approach, utilising proteome, transcriptome and translatome 
data, reduced the as yet uncharacterised genes to ~15%, most 
of which are predicted to be tissue-VSHFLÀF
5. Future perspectives
Single-cell sequencing is now a reality and numerous studies 
are currently being undertaken (121,122). This technology 
provides greater insight into the biology of heterogeneous 
populations of cells, e.g., a tumour, in which many different 
cell states contribute to the overall function. Similarly, 
single-cell proteomic methods are currently being devised, 
utilising an antibody-bound chip, analogous to microarray 
technology (123). These approaches are expected to take 
high-throughput systems biology approaches to new heights 
and will also JHQHUDWHVLJQLÀFDQWO\ larger datasets, for which 
new strategies will be required.
Our ability to interpret the data produced via 
high-throughput experimental technologies is continuously 
improving. There are currently numerous online tools widely 
available for use, such as PepTracker (124), DAVID (125) and 
STRING (126), that allow scientists with minimal under-
standing of bioinformatics to obtain useful data from large 
proteomic datasets. Many of these systems biology-based 
web applications are available free of charge to the academic FRPPXQLW\7KHDLPRIWKH3URWHRPLFV6SHFLÀFDWLRQLQ7LPH
and Space project is to keep improving the utility of large 
datasets through the development of analysis tools and the 
application of new methodologies (127).
The increasing trend towards utilising large-scale systems 
biology across the scientific community has led to an 
increasing availability of OMICS datasets. Indeed, multiple 
projects have been established in order to set up and maintain 
large data repositories, such as the ProteomeXchange and 51$VHT$WODVZHEDSSOLFDWLRQVDOORZLQJWKHZLGHUVFLHQWLÀF
community to use data previously obtained by other groups to 
inform their own research (128,129). This is highlighted by a 
recent study using 42 previously published and 7 unpublished 
Drosophila phenotypes inferred by RNAi screens (130). 7KLVDSSURDFKHQDEOHGD ?VLJQHG 가 SURWHLQSURWHLQLQWHUDFWLRQ
network to be constructed, consisting of 6,125 interactions 
between 3,352 proteins. Subsequent testing of the network 
revealed a high predictive power. As more OMICS datasets 
become freely available, the power of such predictive models 
will increase, as will our collective understanding of the ques-
tions we can answer by using them. It is important to remain 
critical, however, and not rely solely on computational predic-
tion biology. Despite the success of many of these projects, the 
data require validation in a wet lab environment.
Regarding EBV and KSHV, further research using 
large-scale systems biology approaches will help develop 
our understanding of the intricacies of infection. Proteomic 
screens are currently routinely performed and it will be 
of particular interest to view the results of OMICS-based 
analysis of numerous single cells infected with fully 
competent Ƣ-herpesviruses. The challenges arising from 
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this will be validating these studies and attempting to link 
them to clinically relevant applications for these important 
pathogens.
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